{"success":true,"data":{"pressRelease":{"id":"46085","rtpr_id":"nBw57TRjra","ticker":"ARWR","exchange":"NASDAQ","all_tickers":["ARWR"],"title":"Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026","author":"Business Wire","published_at":"2026-05-27T11:00:00.886Z","article_body":"Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and\nMASH Candidate ARO-INHBE at EASL 2026\n\n- Targeting Activin E may represent a novel therapeutic strategy for metabolic\ndysfunction-associated steatohepatitis (MASH) and obesity‑related metabolic\ndysfunction\n\n- ARO-INHBE produced meaningful reductions in liver fat content as a\nmonotherapy or in combination with low-dose tirzepatide in individuals with\nobesity with or without Type 2 Diabetes Mellitus (T2DM)\n\n- Longer exposure to ARO-INHBE silencing resulted in continued improvements in\nvisceral fat and liver fat from Week 12 to Week 24\n\nArrowhead Pharmaceuticals, Inc.\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Farrowheadpharma.com%2Fen-us&esheet=54542518&newsitemid=20260527903149&lan=en-US&anchor=Arrowhead+Pharmaceuticals%2C+Inc.&index=1&md5=d5103d9972000d307778195639d62ee3)\n(NASDAQ: ARWR) today presented interim results from a Phase 1/2a clinical\ntrial of ARO-INHBE, the company’s investigational RNA interference (RNAi)\ntherapeutic being developed as a potential treatment for obesity and metabolic\ndysfunction-associated steatohepatitis (MASH). The data presented at the\nEuropean Association for the Study of the Liver Congress (EASL 2026)\ndemonstrate that ARO-INHBE treatment led to clinically meaningful reductions\nin liver fat as a monotherapy and in combination with low-dose tirzepatide, a\nGLP-1/GIP receptor co-agonist, in adults with obesity. Arrowhead is currently\nengaging with regulatory authorities on additional designs and endpoints for\npotential Phase 2 studies in MASH and obesity.\n\n“Building on prior interim results from a Phase 1/2a study of ARO-INHBE,\nwhich showed encouraging signals on weight loss and improved measures of body\ncomposition in obese patients with diabetes, today we presented additional\nresults at the EASL 2026 congress. These data provide encouraging signals on\nthe safety, activity, and efficacy of ARO-INHBE, particularly with respect to\nliver fat reductions as a monotherapy or in combination with low-dose\ntirzepatide in patients with or without Type 2 Diabetes Mellitus,” said\nJames Hamilton, M.D., MBA, Chief Medical Officer and Head of R&D at\nArrowhead. “We believe that targeting the Activin E/ALK7 pathway, a\ngenetically validated pathway that regulates adipose fat storage, is a\npromising strategy to address MASH and obesity‑related metabolic dysfunction\nand may complement existing incretin-based approaches in the treatment of\nobesity.”\n\nThe EASL 2026 poster may be accessed on the Events and Presentations\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fir.arrowheadpharma.com%2Fevents-and-presentations&esheet=54542518&newsitemid=20260527903149&lan=en-US&anchor=Events+and+Presentations&index=2&md5=0a7e77ed3b24ebf05d3546747079af77)\npage on the Investors section of the Arrowhead website.\n\nSelect ARO-INHBE Phase 1/2a Results\n\n\n * In participants with obesity, dose-dependent reductions in Activin E were\nobserved following a single administration of ARO-INHBE, with a mean maximum\nreduction of 85.3% achieved with ARO-INHBE 400 mg and persistent effect beyond\n3 months\n\n * Similar Activin E reductions were observed in participants with obesity and\nT2DM receiving two doses of ARO-INHBE (200 mg or 400 mg) in combination with\ntirzepatide 5 mg, demonstrating persistent effect through Week 24 with the\npotential for infrequent twice per year dose administration\n\n * Participants with obesity and baseline liver fat content (LFC) greater than 8%\nreceiving 200mg or greater of ARO-INHBE monotherapy (n=10; baseline LFC\n14.5±5.1%) had a placebo-adjusted post-dose LFC reduction of 44% (t-test: p\n< 0.01)\n\n * ARO-INHBE in combination with low-dose tirzepatide (5 mg) resulted in enhanced\nreductions in visceral adipose tissue and LFC compared to tirzepatide alone in\nparticipants with obesity with or without T2DM\n\n * Longer exposure to ARO-INHBE resulted in continued improvements in visceral\nfat and LFC from Week 12 to Week 24\n\nSafety and Tolerability\n\nARO-INHBE has been generally well tolerated to date as a monotherapy and in\ncombination with tirzepatide in participants with obesity with and without\ntype 2 diabetes. Most treatment emergent adverse events (TEAE) were mild in\nseverity. No TEAEs led to study or study drug discontinuation. Injection site\nreactions were generally mild and self-limited.\n\nAbout ARO-INHBE\n\nARO-INHBE is designed to reduce the hepatic expression of the INHBE gene and\nits secreted gene product, Activin E. INHBE is a promising genetically\nvalidated target in which loss-of-function INHBE variants in humans are\nassociated with improved fat distribution and lower risk of metabolic\ndiseases, such as type 2 diabetes. Activin E acts as a ligand in a pathway\nthat regulates energy homeostasis in adipose tissue. Inhibiting this pathway\nwith investigational ARO-INHBE treatment has the potential to increase\nlipolysis, and reduce adipose hypertrophy and dysfunction, visceral adiposity,\nand insulin resistance.\n\nAbout the AROINHBE-1001 Phase 1/2 Study\n\nAROINHBE-1001 (NCT06700538\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06700538%3Fterm%3DNCT06700538%26rank%3D1&esheet=54542518&newsitemid=20260527903149&lan=en-US&anchor=NCT06700538&index=3&md5=0058361837ba44ca01b02d55edea64f5)\n) is a Phase 1/2a dose-escalating study to evaluate the safety, tolerability,\npharmacokinetics, and pharmacodynamics of ARO-INHBE in up to 78 adult\nvolunteers with obesity. Part 1 of the study is designed to assess single and\nmultiple doses of ARO-INHBE monotherapy, and Part 2 of the study is designed\nto assess ARO-INHBE in combination with tirzepatide, a subcutaneously\nadministered GLP-1/GIP receptor co-agonist that has been approved in the\nUnited States and the European Union for management of type 2 diabetes\nmellitus since 2022 and weight management since 2023/2024 respectively.\n\nAbout Arrowhead Pharmaceuticals\n\nArrowhead Pharmaceuticals (NASDAQ: ARWR) is a commercial-stage pharmaceutical\ncompany developing medicines that treat intractable diseases by silencing the\ngenes that cause them, harnessing the natural RNA interference (RNAi)\nmechanism. The company has built a broad portfolio of clinical and commercial\nRNAi therapeutics through its industry-leading targeted RNAi molecule\n(TRiM™) platform, which can precisely silence genes in a wide range of cell\ntypes, including liver, lung, muscle, adipose, and central nervous system\ntissue. At Arrowhead, we rapidly advance potential best- and first-in-class\nRNAi treatments for diseases with significant unmet medical need, because\nevery day matters to the patients we serve.\n\nFor more information, please visit www.arrowheadpharma.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.arrowheadpharma.com%2F&esheet=54542518&newsitemid=20260527903149&lan=en-US&anchor=www.arrowheadpharma.com&index=4&md5=764d8ea156e87678f3ba08e853f2f791)\n, or follow us on X (formerly Twitter) at @ArrowheadPharma\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.twitter.com%2Farrowheadpharma&esheet=54542518&newsitemid=20260527903149&lan=en-US&anchor=%40ArrowheadPharma&index=5&md5=7b672c152328a1cbb0c3df4092dcc574)\n, LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Farrowhead-pharmaceuticals%2F&esheet=54542518&newsitemid=20260527903149&lan=en-US&anchor=LinkedIn&index=6&md5=5f95dd3fb6d9ebb302b961f3d56659cd)\n, Facebook\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2FArrowheadPharma%2F&esheet=54542518&newsitemid=20260527903149&lan=en-US&anchor=Facebook&index=7&md5=7b55492fe3bb70e5dc7c7a33b0a5b5af)\n, and Instagram\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.instagram.com%2Farrowheadpharma%2F&esheet=54542518&newsitemid=20260527903149&lan=en-US&anchor=Instagram&index=8&md5=f5596a0c31c2f0ddf8bd871c9c5b5d84)\n. To be added to the Company's email list and receive news directly, please\nvisit http://ir.arrowheadpharma.com/email-alerts\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fir.arrowheadpharma.com%2Femail-alerts&esheet=54542518&newsitemid=20260527903149&lan=en-US&anchor=http%3A%2F%2Fir.arrowheadpharma.com%2Femail-alerts&index=9&md5=776853e36680056e3d8cacea3b619e9a)\n.\n\nSafe Harbor Statement under the Private Securities Litigation Reform Act:\n\nThis news release contains forward-looking statements within the meaning of\nthe \"safe harbor\" provisions of the Private Securities Litigation Reform Act\nof 1995. Any statements contained in this release except for historical\ninformation may be deemed to be forward-looking statements. Without limiting\nthe generality of the foregoing, words such as “may,” “will,”\n“expect,” “believe,” “anticipate,” “hope,” “intend,”\n“plan,” “project,” “could,” “estimate,” “continue,”\n“target,” “forecast” or “continue” or the negative of these words\nor other variations thereof or comparable terminology are intended to identify\nsuch forward-looking statements. In addition, any statements that refer to\nprojections of our future financial performance, trends in our business,\nexpectations for our product pipeline, products or product candidate or other\ncharacterizations of future events or circumstances are forward-looking\nstatements. These statements are based upon our current expectations and speak\nonly as of the date hereof. Actual results or outcomes may differ materially\nand adversely from those expressed in any forward-looking statements as a\nresult of numerous factors and uncertainties the safety and efficacy of our\nproducts and product candidates, pricing and reimbursement decisions related\nto our products, demand for our products, decisions of regulatory authorities\nand the timing thereof, the duration and impact of regulatory delays in our\nclinical programs, our ability to finance our operations, the likelihood and\ntiming of the receipt of future milestone and licensing fees, the future\nsuccess of our scientific studies, the timing for starting and completing\nclinical trials, rapid technological change in our markets, the enforcement of\nour intellectual property rights, and the other risks and uncertainties\ndescribed in our most recent Annual Report on Form 10-K, subsequent Quarterly\nReports on Form 10-Q and other documents filed with the Securities and\nExchange Commission from time to time. We assume no obligation to update or\nrevise forward-looking statements to reflect new events or circumstances.\n\nSource: Arrowhead Pharmaceuticals, Inc.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260527903149/en/\n(https://www.businesswire.com/news/home/20260527903149/en/)\n\nArrowhead Pharmaceuticals, Inc.\n\nVince Anzalone, CFA\n\n626-304-3400\n\nir@arrowheadpharma.com (mailto:ir@arrowheadpharma.com)\n\nInvestors: \n\nLifeSci Advisors, LLC\n\nBrian Ritchie \n\n212-915-2578\n\nbritchie@lifesciadvisors.com (mailto:britchie@lifesciadvisors.com)\n\nMedia: \n\nLifeSci Communications, LLC\n\nKendy Guarinoni, Ph.D.\n\n724-910-9389\n\nkguarinoni@lifescicomms.com (mailto:kguarinoni@lifescicomms.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw57TRjra","title":"Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026","author":"Business Wire","ticker":"ARWR","created":"2026-05-27T11:00:00.886Z","tickers":["ARWR"],"exchange":"NASDAQ","article_body":"Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and\nMASH Candidate ARO-INHBE at EASL 2026\n\n- Targeting Activin E may represent a novel therapeutic strategy for metabolic\ndysfunction-associated steatohepatitis (MASH) and obesity‑related metabolic\ndysfunction\n\n- ARO-INHBE produced meaningful reductions in liver fat content as a\nmonotherapy or in combination with low-dose tirzepatide in individuals with\nobesity with or without Type 2 Diabetes Mellitus (T2DM)\n\n- Longer exposure to ARO-INHBE silencing resulted in continued improvements in\nvisceral fat and liver fat from Week 12 to Week 24\n\nArrowhead Pharmaceuticals, Inc.\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Farrowheadpharma.com%2Fen-us&esheet=54542518&newsitemid=20260527903149&lan=en-US&anchor=Arrowhead+Pharmaceuticals%2C+Inc.&index=1&md5=d5103d9972000d307778195639d62ee3)\n(NASDAQ: ARWR) today presented interim results from a Phase 1/2a clinical\ntrial of ARO-INHBE, the company’s investigational RNA interference (RNAi)\ntherapeutic being developed as a potential treatment for obesity and metabolic\ndysfunction-associated steatohepatitis (MASH). The data presented at the\nEuropean Association for the Study of the Liver Congress (EASL 2026)\ndemonstrate that ARO-INHBE treatment led to clinically meaningful reductions\nin liver fat as a monotherapy and in combination with low-dose tirzepatide, a\nGLP-1/GIP receptor co-agonist, in adults with obesity. Arrowhead is currently\nengaging with regulatory authorities on additional designs and endpoints for\npotential Phase 2 studies in MASH and obesity.\n\n“Building on prior interim results from a Phase 1/2a study of ARO-INHBE,\nwhich showed encouraging signals on weight loss and improved measures of body\ncomposition in obese patients with diabetes, today we presented additional\nresults at the EASL 2026 congress. These data provide encouraging signals on\nthe safety, activity, and efficacy of ARO-INHBE, particularly with respect to\nliver fat reductions as a monotherapy or in combination with low-dose\ntirzepatide in patients with or without Type 2 Diabetes Mellitus,” said\nJames Hamilton, M.D., MBA, Chief Medical Officer and Head of R&D at\nArrowhead. “We believe that targeting the Activin E/ALK7 pathway, a\ngenetically validated pathway that regulates adipose fat storage, is a\npromising strategy to address MASH and obesity‑related metabolic dysfunction\nand may complement existing incretin-based approaches in the treatment of\nobesity.”\n\nThe EASL 2026 poster may be accessed on the Events and Presentations\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fir.arrowheadpharma.com%2Fevents-and-presentations&esheet=54542518&newsitemid=20260527903149&lan=en-US&anchor=Events+and+Presentations&index=2&md5=0a7e77ed3b24ebf05d3546747079af77)\npage on the Investors section of the Arrowhead website.\n\nSelect ARO-INHBE Phase 1/2a Results\n\n\n * In participants with obesity, dose-dependent reductions in Activin E were\nobserved following a single administration of ARO-INHBE, with a mean maximum\nreduction of 85.3% achieved with ARO-INHBE 400 mg and persistent effect beyond\n3 months\n\n * Similar Activin E reductions were observed in participants with obesity and\nT2DM receiving two doses of ARO-INHBE (200 mg or 400 mg) in combination with\ntirzepatide 5 mg, demonstrating persistent effect through Week 24 with the\npotential for infrequent twice per year dose administration\n\n * Participants with obesity and baseline liver fat content (LFC) greater than 8%\nreceiving 200mg or greater of ARO-INHBE monotherapy (n=10; baseline LFC\n14.5±5.1%) had a placebo-adjusted post-dose LFC reduction of 44% (t-test: p\n< 0.01)\n\n * ARO-INHBE in combination with low-dose tirzepatide (5 mg) resulted in enhanced\nreductions in visceral adipose tissue and LFC compared to tirzepatide alone in\nparticipants with obesity with or without T2DM\n\n * Longer exposure to ARO-INHBE resulted in continued improvements in visceral\nfat and LFC from Week 12 to Week 24\n\nSafety and Tolerability\n\nARO-INHBE has been generally well tolerated to date as a monotherapy and in\ncombination with tirzepatide in participants with obesity with and without\ntype 2 diabetes. Most treatment emergent adverse events (TEAE) were mild in\nseverity. No TEAEs led to study or study drug discontinuation. Injection site\nreactions were generally mild and self-limited.\n\nAbout ARO-INHBE\n\nARO-INHBE is designed to reduce the hepatic expression of the INHBE gene and\nits secreted gene product, Activin E. INHBE is a promising genetically\nvalidated target in which loss-of-function INHBE variants in humans are\nassociated with improved fat distribution and lower risk of metabolic\ndiseases, such as type 2 diabetes. Activin E acts as a ligand in a pathway\nthat regulates energy homeostasis in adipose tissue. Inhibiting this pathway\nwith investigational ARO-INHBE treatment has the potential to increase\nlipolysis, and reduce adipose hypertrophy and dysfunction, visceral adiposity,\nand insulin resistance.\n\nAbout the AROINHBE-1001 Phase 1/2 Study\n\nAROINHBE-1001 (NCT06700538\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06700538%3Fterm%3DNCT06700538%26rank%3D1&esheet=54542518&newsitemid=20260527903149&lan=en-US&anchor=NCT06700538&index=3&md5=0058361837ba44ca01b02d55edea64f5)\n) is a Phase 1/2a dose-escalating study to evaluate the safety, tolerability,\npharmacokinetics, and pharmacodynamics of ARO-INHBE in up to 78 adult\nvolunteers with obesity. Part 1 of the study is designed to assess single and\nmultiple doses of ARO-INHBE monotherapy, and Part 2 of the study is designed\nto assess ARO-INHBE in combination with tirzepatide, a subcutaneously\nadministered GLP-1/GIP receptor co-agonist that has been approved in the\nUnited States and the European Union for management of type 2 diabetes\nmellitus since 2022 and weight management since 2023/2024 respectively.\n\nAbout Arrowhead Pharmaceuticals\n\nArrowhead Pharmaceuticals (NASDAQ: ARWR) is a commercial-stage pharmaceutical\ncompany developing medicines that treat intractable diseases by silencing the\ngenes that cause them, harnessing the natural RNA interference (RNAi)\nmechanism. The company has built a broad portfolio of clinical and commercial\nRNAi therapeutics through its industry-leading targeted RNAi molecule\n(TRiM™) platform, which can precisely silence genes in a wide range of cell\ntypes, including liver, lung, muscle, adipose, and central nervous system\ntissue. At Arrowhead, we rapidly advance potential best- and first-in-class\nRNAi treatments for diseases with significant unmet medical need, because\nevery day matters to the patients we serve.\n\nFor more information, please visit www.arrowheadpharma.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.arrowheadpharma.com%2F&esheet=54542518&newsitemid=20260527903149&lan=en-US&anchor=www.arrowheadpharma.com&index=4&md5=764d8ea156e87678f3ba08e853f2f791)\n, or follow us on X (formerly Twitter) at @ArrowheadPharma\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.twitter.com%2Farrowheadpharma&esheet=54542518&newsitemid=20260527903149&lan=en-US&anchor=%40ArrowheadPharma&index=5&md5=7b672c152328a1cbb0c3df4092dcc574)\n, LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Farrowhead-pharmaceuticals%2F&esheet=54542518&newsitemid=20260527903149&lan=en-US&anchor=LinkedIn&index=6&md5=5f95dd3fb6d9ebb302b961f3d56659cd)\n, Facebook\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2FArrowheadPharma%2F&esheet=54542518&newsitemid=20260527903149&lan=en-US&anchor=Facebook&index=7&md5=7b55492fe3bb70e5dc7c7a33b0a5b5af)\n, and Instagram\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.instagram.com%2Farrowheadpharma%2F&esheet=54542518&newsitemid=20260527903149&lan=en-US&anchor=Instagram&index=8&md5=f5596a0c31c2f0ddf8bd871c9c5b5d84)\n. To be added to the Company's email list and receive news directly, please\nvisit http://ir.arrowheadpharma.com/email-alerts\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fir.arrowheadpharma.com%2Femail-alerts&esheet=54542518&newsitemid=20260527903149&lan=en-US&anchor=http%3A%2F%2Fir.arrowheadpharma.com%2Femail-alerts&index=9&md5=776853e36680056e3d8cacea3b619e9a)\n.\n\nSafe Harbor Statement under the Private Securities Litigation Reform Act:\n\nThis news release contains forward-looking statements within the meaning of\nthe \"safe harbor\" provisions of the Private Securities Litigation Reform Act\nof 1995. Any statements contained in this release except for historical\ninformation may be deemed to be forward-looking statements. Without limiting\nthe generality of the foregoing, words such as “may,” “will,”\n“expect,” “believe,” “anticipate,” “hope,” “intend,”\n“plan,” “project,” “could,” “estimate,” “continue,”\n“target,” “forecast” or “continue” or the negative of these words\nor other variations thereof or comparable terminology are intended to identify\nsuch forward-looking statements. In addition, any statements that refer to\nprojections of our future financial performance, trends in our business,\nexpectations for our product pipeline, products or product candidate or other\ncharacterizations of future events or circumstances are forward-looking\nstatements. These statements are based upon our current expectations and speak\nonly as of the date hereof. Actual results or outcomes may differ materially\nand adversely from those expressed in any forward-looking statements as a\nresult of numerous factors and uncertainties the safety and efficacy of our\nproducts and product candidates, pricing and reimbursement decisions related\nto our products, demand for our products, decisions of regulatory authorities\nand the timing thereof, the duration and impact of regulatory delays in our\nclinical programs, our ability to finance our operations, the likelihood and\ntiming of the receipt of future milestone and licensing fees, the future\nsuccess of our scientific studies, the timing for starting and completing\nclinical trials, rapid technological change in our markets, the enforcement of\nour intellectual property rights, and the other risks and uncertainties\ndescribed in our most recent Annual Report on Form 10-K, subsequent Quarterly\nReports on Form 10-Q and other documents filed with the Securities and\nExchange Commission from time to time. We assume no obligation to update or\nrevise forward-looking statements to reflect new events or circumstances.\n\nSource: Arrowhead Pharmaceuticals, Inc.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260527903149/en/\n(https://www.businesswire.com/news/home/20260527903149/en/)\n\nArrowhead Pharmaceuticals, Inc.\n\nVince Anzalone, CFA\n\n626-304-3400\n\nir@arrowheadpharma.com (mailto:ir@arrowheadpharma.com)\n\nInvestors: \n\nLifeSci Advisors, LLC\n\nBrian Ritchie \n\n212-915-2578\n\nbritchie@lifesciadvisors.com (mailto:britchie@lifesciadvisors.com)\n\nMedia: \n\nLifeSci Communications, LLC\n\nKendy Guarinoni, Ph.D.\n\n724-910-9389\n\nkguarinoni@lifescicomms.com (mailto:kguarinoni@lifescicomms.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-05-27T11:00:00.979168643Z","server_sent_at_ms":1779879600979},"received_at":"2026-05-27T11:00:01.216Z","source_url":"https://www.businesswire.com/news/home/20260527903149/en/"},"analysis":{"id":"35520","press_release_id":"46085","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Arrowhead presented interim Phase 1/2a data for ARO-INHBE at EASL 2026, showing a 44% placebo-adjusted reduction in liver fat content in obese patients with baseline liver fat >8%.\n\nThe RNAi therapy also demonstrated dose-dependent Activin E reductions of up to 85.3% and enhanced visceral fat reduction when combined with low-dose tirzepatide.\n\nThe drug was well-tolerated with no discontinuations due to adverse events, supporting the company's plan to engage regulators on Phase 2 designs for MASH and obesity.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Early-stage RNAi obesity/MASH candidate shows strong liver fat reduction and clean safety profile in Phase 1/2a."},"keyFigures":{"drugName":"ARO-INHBE","phaseOfTrial":"Phase 1/2a","customDimensions":{"study_population_size":78,"activin_e_reduction_max":"85.3%","liver_fat_reduction_placebo_adjusted":"44%"}},"quotedText":"These data provide encouraging signals on the safety, activity, and efficacy of ARO-INHBE, particularly with respect to liver fat reductions as a monotherapy or in combination with low-dose tirzepatide in patients with or without Type 2 Diabetes Mellitus","namedEntities":{"people":[{"name":"James Hamilton","role":"Chief Medical Officer and Head of R&D"},{"name":"Vince Anzalone","role":"Investor Relations"},{"name":"Brian Ritchie","role":"LifeSci Advisors"},{"name":"Kendy Guarinoni","role":"LifeSci Communications"}],"products":["ARO-INHBE","tirzepatide"],"companies":[{"name":"Arrowhead Pharmaceuticals, Inc.","ticker":"ARWR"},{"name":"European Association for the Study of the Liver","relationship":"conference host"},{"name":"LifeSci Advisors, LLC","relationship":"investor relations advisor"},{"name":"LifeSci Communications, LLC","relationship":"media relations advisor"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Positive Phase 1/2a interim data showing meaningful liver fat reduction (44% placebo-adjusted) and safety in a novel RNAi obesity/MASH candidate. This is a pre-competitive, early-stage readout, not a pivotal Phase 3 or binary regulatory event, hence score 3 rather than 5."},"tickerRelevance":{"others":[],"primary":"ARWR"},"globalImportance":45,"audienceRelevance":55,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"positive_clinical_data","sectorWeight":"high","householdBrandBoost":"low","marketCapAdjustment":"neutral","retailFavoriteBoost":"low"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Arrowhead presented interim Phase 1/2a data for ARO-INHBE at EASL 2026, showing a 44% placebo-adjusted reduction in liver fat content in obese patients with baseline liver fat >8%.\n\nThe RNAi therapy also demonstrated dose-dependent Activin E reductions of up to 85.3% and enhanced visceral fat reduction when combined with low-dose tirzepatide.\n\nThe drug was well-tolerated with no discontinuations due to adverse events, supporting the company's plan to engage regulators on Phase 2 designs for MASH and obesity.","key_figures":{"drugName":"ARO-INHBE","phaseOfTrial":"Phase 1/2a","customDimensions":{"study_population_size":78,"activin_e_reduction_max":"85.3%","liver_fat_reduction_placebo_adjusted":"44%"}},"named_entities":{"people":[{"name":"James Hamilton","role":"Chief Medical Officer and Head of R&D"},{"name":"Vince Anzalone","role":"Investor Relations"},{"name":"Brian Ritchie","role":"LifeSci Advisors"},{"name":"Kendy Guarinoni","role":"LifeSci Communications"}],"products":["ARO-INHBE","tirzepatide"],"companies":[{"name":"Arrowhead Pharmaceuticals, Inc.","ticker":"ARWR"},{"name":"European Association for the Study of the Liver","relationship":"conference host"},{"name":"LifeSci Advisors, LLC","relationship":"investor relations advisor"},{"name":"LifeSci Communications, LLC","relationship":"media relations advisor"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-27T11:03:17.774Z","global_importance":45,"audience_relevance":55,"importance_components":{"tickerTier":"mid-cap","eventGravity":"positive_clinical_data","sectorWeight":"high","householdBrandBoost":"low","marketCapAdjustment":"neutral","retailFavoriteBoost":"low"}},"durationMs":47006,"modelName":"george-droid-qwen-72b"}}